New Opportunities for Minimizing Toxicity in Rectal Cancer Management
American Society of Clinical Oncology Educational Book · 2023-06 · (43)
DOI: 10.1200/edbk_389558 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Society of Clinical Oncology Educational Book, 2023-06. Verfasst von Alice M Couwenberg und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Rectal Neoplasms, Brain Neoplasms, Neoplasms, Second Primary. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Advances in multimodal management of locally advanced rectal cancer (LARC), consisting of preoperative chemotherapy and/or radiotherapy followed by surgery with or without adjuvant chemotherapy, have improved local disease control and patient survival but are associated with significant risk for acute and long-term morbidity. Recently published trials, evaluating treatment dose intensification via the addition of preoperative induction or consolidation chemotherapy (total neoadjuvant therapy [TNT]), have demonstrated improved tumor response rates while maintaining acceptable toxicity. In addition, TNT has led to an increased number of patients achieving a clinical complete response and thus eligible to pursue a nonoperative, organ-preserving, watch and wait approach, thereby avoiding toxicities associated with surgery, such as bowel dysfunction and stoma-related complications. Ongoing trials using immune checkpoint inhibitors in patients with mismatch repair-deficient tumors suggest that this subgroup of patients with LARC could potentially be treated with immunotherapy alone, sparing them the toxicity associated with preoperative treatment and surgery. However, the majority of rectal cancers are mismatch repair-proficient and less responsive to immune checkpoint inhibitors and require multimodal management. The synergy noted in preclinical studies between immunotherapy and radiotherapy on immunogenic tumor cell death has led to the design of ongoing clinical trials that explore the benefit of combining radiotherapy, chemotherapy, and immunotherapy (mainly of immune checkpoint inhibitors) and aim to increase the number of patients eligible for organ preservation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, NC.
- Vanderbilt University Medical Center/Vanderbilt-Ingram Cancer Center, Nashville, TN.
- Department of Radiation Oncology, Leiden University Medical Center, Leiden, The Netherlands.
- Department of Surgery, Lineberger Comprehensive Cancer Center, University of North Carolina-Chapel Hill, Chapel Hill, NC.
ORCID-Profile: Dimitrios N Varvoglis
Förderung
- NCI NIH HHS
Zitieren
APA
Couwenberg, A. M., Varvoglis, D. N., Grieb, B. C., Marijnen, C. A. M., Ciombor, K. K., & Guillem, J. G. (2023). New Opportunities for Minimizing Toxicity in Rectal Cancer Management. American Society of Clinical Oncology Educational Book. https://doi.org/10.1200/edbk_389558
Vancouver
Couwenberg AM, Varvoglis DN, Grieb BC, Marijnen CAM, Ciombor KK, Guillem JG. New Opportunities for Minimizing Toxicity in Rectal Cancer Management. American Society of Clinical Oncology Educational Book. 2023. doi:10.1200/edbk_389558
BibTeX
@article{Couwenberg2023,
author = {Couwenberg, Alice M and Varvoglis, Dimitrios N and Grieb, Brian C and Marijnen, Corrie A M and Ciombor, Kristen K and Guillem, Jose G},
title = {New Opportunities for Minimizing Toxicity in Rectal Cancer Management},
journal = {American Society of Clinical Oncology Educational Book},
year = {2023},
number = {43},
doi = {10.1200/edbk_389558}
}
EUVIMED